Table 3.
Survival outcome by treatment arm: 3- (n = 1364) and 5-year (n = 1178) landmark analyses*
| Variable | Prostate cancer–specific death | Other deaths | Total deaths |
| 3-y Landmark analysis | |||
| No. of deaths (%) | |||
| Control arm | 107 (8) | 246 (18) | 353 (26) |
| Experimental arm | 76 (6) | 260 (19) | 336 (25) |
| HR (95% CI) | 0.69 (0.52 to 0.93) | 0.92 (0.79 to 1.07) | |
| Death rates,† % (95% CI) | |||
| Control arm | 14.04 (11.37 to 16.72) | 29.26 (25.74 to 32.77) | |
| Experimental arm | 9.96 (7.63 to 12.28) | 30.70 (27.10 to 34.29) | |
| Median survival time,‡ y (95% CI) | 9.73 (7.63 to 13.98) | ||
| Median time to event time, y (95% CI) | 6.97 (3.04 to 12.90) | 7.53 (3.00 to 13.65) | 7.42 (3.00 to 13.65) |
| 5-y Landmark analysis | |||
| No. of deaths (%) | |||
| Control arm | 74 (6) | 187 (16) | 261 (22) |
| Experimental arm | 56 (5) | 202 (17) | 258 (22) |
| HR (95% CI) | 0.73 (0.52 to 1.04) | 0.95 (0.80 to 1.13) | |
| Death rates,† % (95% CI) | |||
| Control arm | 10.64 (8.07 to 13.22) | 23.83 (20.26 to 27.39) | |
| Experimental arm | 7.90 (5.65 to 10.15) | 24.98 (21.36 to 28.60) | |
| Median survival time,‡ y (95% CI) | 10.41 (5.00 to 13.98) | ||
| Median time to event time, y (95% CI) | 8.15 (5.00 to 12.90) | 8.49 (5.00 to 13.65) | 8.43 (5.00 to 13.65) |
*
Control arm = short-term androgen deprivation and radiation therapy; experimental arm = long-term androgen deprivation and radiation therapy; HR = hazard ratio of death; CI = confidence interval.
†
Death rates at 10 years.
‡
Median survival time for all patients in the 3-year landmark analysis (n = 1364) and the 5-year landmark analysis (n = 1178).